Unlike prior trials in more experimental settings, the new JMIR study is the first peer-reviewed real-world evaluation of an autonomous GenAI chatbot, Limbic Care, supporting scaled mental healthcare within an established care model in the NHS-demonstrating its effectiveness compared to non-GenAI treatment.
The first real-world study on the use of Generative Artificial Intelligence (GenAI) in mental health treatment within a live, multi-site clinical setting has been published in JMIR Publications. The research found that patients receiving care augmented by GenAI attended 42% more therapy sessions and achieved a 25% higher recovery rate compared to standard treatment. These findings demonstrate GenAI's ability to enhance clinical outcomes and elevate the standard of care within an established healthcare system-the UK's National Health Service (NHS).
The study compared 150 patients using Limbic Care, a GenAI-powered therapy companion delivering Cognitive Behavioral Therapy (CBT) tools across five NHS Talking Therapies services in England, with 94 patients who received standard, static CBT exercises. Published in JMIR Publications under the title "Generative AI-Enabled Therapy Support Tool Improves Clinical Outcomes and Patient Engagement in NHS Group Therapy: Real-World Observational Study" the research assessed whether GenAI could improve patient outcomes in CBT over a structured, six-session treatment plan. Unlike prior research conducted in artificial or highly controlled settings, this study evaluated GenAI's impact in real-world clinical practice as an adjunct to the standard model of care.
The findings demonstrated that Limbic Care's GenAI:
- Increased session attendance by 42%
- Decreased dropout rates by 23%
- Improved recovery rates by 25%
- Increased reliable improvement rates and reliable recovery rates by 21%
- Reduced Did Not Attend (DNA) rates by 15%
- Generated an estimated £228 of additional value per patient, based on improved recovery rates alone
"One of the leading worries therapists share is how their patients are handling the pressures facing them outside of our time guiding their treatment," said Mona Stylianou, Principal Clinical Lead for Everyturn Mental Health, a non-profit provider of mental health services for the NHS. "Seeing Limbic Care elevate the standards of care for patients at home, including chat support for times of crisis, helps provide peace of mind for our therapy leaders."
Based on a treatment plan created and led by a mental health professional, Limbic Care uses GenAI to tailor treatment and provide therapeutic materials, with communication via a chat interface. The user experience is personalized based on patient feedback and clinical insights.
"Demonstrating that GenAI can safely and effectively augment real-world mental healthcare across multiple diagnoses within an established national health system represents a major step forward in AI-assisted therapy," said Limbic CEO Ross Harper. "This isn't about naive substitution, this research shows that AI can amplify the work of clinicians treating patients right now. It provides hope for our overburdened care systems through fundamental change within existing clinical structures."
About Limbic
Limbic is making the highest quality mental healthcare available to everyone, everywhere, regardless of socioeconomic factors. Limbic Access is the world's first AI mental health chatbot to have achieved Class IIa UK medical device status and has helped over 400,000 NHS patients enter care, releasing over 70,000 clinical hours for NHS services and saving 5 to 10 times the economic cost per additional user recovery.
Limbic is a venture-funded company backed by global investors, including Khosla Ventures, and is dual headquartered across the U.S. and U.K.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250310848349/en/
Contacts:
Media Contact:
limbic@consortpartners.com
